
Analytical Method Validation for Biopharmaceuticals, Part 3

Drew N. Kelner Ira S. Krull Robert J. Duff¹

By

Tamer Eris Apr 25, 2017 10:24 am PDT



Over the history of the biotechnology industry, biopharmaceutical companies have expended considerable effort characterizing and tracking the entire suite of product attributes using available technology, uncertain of the biological significance of the various attributes. Product specifications for purity were based on chromatographic patterns capable of tracking the consistency of manufacturing, but unable to track specific attributes, due to the heterogeneous nature of the chromatographic peaks.

IVT's **Analytical Procedures & Methods Validation** event on 20-22 June, 2017 in Dublin, Ireland offers attendees interactive workshops and critical discussions, including an FDA keynote address and breakdowns of global regulatory updates.

You May Also Like: [Part 2](#)

Source URL: <http://www.ivtnetwork.com/article/analytical-method-validation-biopharmaceuticals-part-3>